Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 3 (1)

Trial Status

Not Yet Recruiting2
Recruiting2
Unknown1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07463872Recruiting

Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data

NCT07014709Not Yet Recruiting

Impact of GLP-1 Receptor Agonists on Patients With IPMN

NCT06162468Not ApplicableNot Yet RecruitingPrimary

Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts

NCT06706700RecruitingPrimary

Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas

NCT05914077Phase 3UnknownPrimary

Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.

Showing all 5 trials

Research Network

Activity Timeline